2024年9月7-10日，由国际肺癌研究协会(IASLC)举办的2024世界肺癌大会(WCLC)将于美国圣迭戈隆重召开。作为全球规模最大的肿瘤领域学术会议之一，WCLC大会吸引着全球专家学者的目光，来自全球100多个国家的近万名专业人士，共同探讨肺癌领域的最新研究成果和突破，推动肿瘤学科的全球发展。

近期，WCLC年会官网已公布部分摘要标题及作者信息，其中来自中国的60多位专家将在会议中展示其创新研究成果。梅斯医学整理了部分口头报告，一起来看看。

摘要号：PL02.04
标题：Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: Primary Analysis of HARMONi-2
讲者：周彩存（同济大学附属东方医院）

摘要号：PL04.07
标题：FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations
讲者：王洁（中国医学科学院肿瘤医院）

摘要号：PL04.10
标题：Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial
讲者：杨衿记（广东省人民医院）

摘要号：OA01.04
标题：Phase II Study of Perioperative Ivonescimab Alone or Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer
讲者：赵晓亮（天津医科大学肿瘤医院）

摘要号：OA02.03
标题：Phase III Study of Rilertinib Versus Gefitinib as First-Line Therapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC
讲者：熊安稳（上海市肺科医院）

摘要号：OA05.05
标题：Pre-Local Consolidative Therapy Circulating Circulating Tumor DNA Defines Molecular Oligometastatic Non-Small Cell Lung Cancer
讲者：傅睿（广东省人民医院）

摘要号：OA06.03
标题：SAFFRON-301: Tislelizumab Plus Sitravatinib in Advanced/Metastatic NSCLC Progressing on/after Chemotherapy and Anti-PD-(L)1
讲者：吴一龙（广东省人民医院）

摘要号：MA05.03
标题： A Phase II Study of Tislelizumab Combined with Chemotherapy in Patients with Thymic Carcinoma
讲者：邬麟（湖南省肿瘤医院）

摘要号：OA07.05
标题：Phase 3 Study of HR20013 For Prevention of Cisplatin-based Chemotherapy-induced Nausea and Vomiting (PROFIT Study)
讲者：张力（中山大学肿瘤防治中心）

摘要号：MA11.07
标题：Preliminary Efficacy and Safety of SHR-1701 Plus Fluzoparib as Maintenance Therapy for Patients with Advanced Lung Squamous Cell Carcinoma
讲者：张永昌（湖南省肿瘤医院）

摘要号：MA11.10
标题：Benmelstobart, a PD-L1 Mab, Plus Anlotinib in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies:Phase II Results Update
讲者：史美祺（江苏省肿瘤医院）

摘要号：MA15.04
标题：MRD Predicts Clinical Outcomes of Patients with Early-Stage EGFR-Mutant NSCLC: A Post-Hoc Biomarker Analyses of EVIDENCE MRD
讲者：周斐（上海市东方医院）

摘要号：MA15.05
标题：Follow-Up Update of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer
讲者：张嘉涛（广东省人民医院）

摘要号：MA17.06
标题：Durvalumab Plus Anlotinib Versus Durvalumab as Maintenance Treatment in ES-SCLC (DURABLE): A Randomized, Phase 2 Trial
讲者：韩宝惠（上海交通大学附属胸科医院）

摘要号：MA17.07
标题：Safety and Efficacy of Tifcemalimab Combined with Toripalimab in Refractory Extensive Stage Small Cell Lung Cancer
讲者：张立新（吉林省肿瘤医院）

摘要号：MA06.11
标题：Phase II Trial of Ensartinib for Advanced or Metastatic Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
讲者： 夏旸（浙江大学医学院附属第二医院）

摘要号：MA07.04
标题：Targeting CD24 Enhances the Response to Third-Generation Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer
讲者：梁嘉琪（复旦大学附属中山医院）

摘要号：MA07.08
标题：Proteogenomic Analysis of CSF Reveals Distinct Molecular Patterns of Leptomeningeal Metastases in EGFR-Mutated NSCLC 
讲者：郑媚美（广东省人民医院）

摘要号：MA07.12
标题：Unleashing the Potential of the Probiotic F.prausnitzii to Optimize PD-1 Inhibitor Efficacy in NSCLC Treatment
讲者：姜龙（上海交通大学医学院附属胸科医院）

摘要号：MA07.13
标题：Neoadjuvant Chemotherapy Is Associated with Optimized Spatial Landscape of Tissue-Resident Memory T Cells in Non-Small Cell Lung Cancer
讲者：邢力刚（山东第一医科大学附属肿瘤医院）

Tags： WCLC 2024 | 中国肺癌之声：60+项口头报告闪耀国际舞台